Minerva Surgical, Inc. (UTRS)

NASDAQ: UTRS · IEX Real-Time Price · USD
-0.072 (-16.74%)
At close: Jan 27, 2023, 4:00 PM
+0.002 (0.56%)
After-hours: Jan 27, 2023, 7:52 PM EST

Company Description

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States.

The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.

Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices.

The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Minerva Surgical, Inc.
Minerva Surgical logo
Country United States
Founded 2008
IPO Date Oct 22, 2021
Industry Health Information Services
Sector Healthcare
Employees 157
CEO Mr. David M. Clapper

Contact Details

4255 Burton Drive
Santa Clara, California 95054
United States
Phone (855) 646-7874
Website minervasurgical.com

Stock Details

Ticker Symbol UTRS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $12.00
CIK Code 0001452965
CUSIP Number 60343F106
ISIN Number US60343F1066
Employer ID 26-3422906
SIC Code 3841

Key Executives

Name Position
David M. Clapper President, Chief Executive Officer and Director
Joel R. Jung MBA Chief Financial Officer
Dominique J. Filloux Chief Operating Officer
Thomas Pendlebury Vice President of Sales and Marketing
Wendy Bowman Vice President of Human Resources
Joanne Long Vice President of Corporate Controller
Dr. Evgueni V. Skalnyi M.D. Vice President of Medical Affairs

Latest SEC Filings

Date Type Title
Jan 24, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jan 23, 2023 DEF 14A Other definitive proxy statements
Jan 17, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 17, 2023 8-K Current Report
Jan 13, 2023 PRE 14A Other preliminary proxy statements
Dec 30, 2022 8-K Current Report
Dec 28, 2022 8-K Current Report
Dec 28, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Dec 28, 2022 8-K Current Report
Nov 16, 2022 8-K/A [Amend] Current report